Autolus Therapeutics
AUTL
96 hedge funds and large institutions have $234M invested in Autolus Therapeutics in 2025 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 34 increasing their positions, 24 reducing their positions, and 12 closing their positions.
398% more call options, than puts
Call options by funds: $488K | Put options by funds: $98K
42% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 24
17% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 12
2% more funds holding
Funds holding: 94 → 96 (+2)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
8% less ownership
Funds ownership: 62.39% → 54.39% (-8%)
38% less capital invested
Capital invested by funds: $379M → $234M (-$145M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCO
MAK Capital One
New York
|
+$17.7M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$9.85M |
| 3 |
Schroder Investment Management Group
London,
United Kingdom
|
+$9.43M |
| 4 |
AC
Armistice Capital
New York
|
+$7.03M |
| 5 |
Renaissance Technologies
New York
|
+$6.12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$61.9M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$27.9M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$16.2M |
| 4 |
Axa
Paris,
France
|
-$7.13M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$6.14M |
AUTL Hedge Fund Activity: Q3 2025 in Review
96 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Autolus Therapeutics (AUTL) for Q3 2025, worth a combined $234M — down 38% from $379M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new AUTL positions and 12 closed out — a net gain of 2 holders — while 34 added to existing stakes and 24 trimmed.
The largest buyer was MAK Capital One, adding an estimated $17.7M. The largest seller was Wellington Management Group, exiting entirely with an estimated $61.9M sold.
- 96 institutional investors held Autolus Therapeutics (AUTL) as of Q3 2025, up from 94 in Q2 2025.
- Funds reported $234M of Autolus Therapeutics stock for Q3 2025, down 38% quarter-over-quarter.
- 14 funds opened new Autolus Therapeutics positions in Q3 2025 and 12 closed out, a net change of +2 holders.
- The largest Autolus Therapeutics buyer in Q3 2025 was MAK Capital One, an estimated $17.7M added.
- The largest Autolus Therapeutics seller in Q3 2025 was Wellington Management Group, an estimated $61.9M sold.
Based on aggregated 13F filings for Q3 2025.